Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a late-stage pharmaceutical company with a broad ...

Two posters presented at the 2024 American Society of Hematology meeting reported real-world outcomes data for patients ...

Interesting trends were observed in the subgroup analyses of the phase 3 uproleselan study in relapsed or refractory acute ...

Young patients with low-risk, relapsed Hodgkin lymphoma may be able to avoid transplant, data from 3 studies suggest.

A new study evaluating the quadratic phenotypic optimization platform shows it can accurately predict personalized drug ...

A phase 3 trial confirms “the potent anti-leukemic effect” of consolidation with allogeneic transplant in older patients with acute myeloid leukemia, according to researchers.

Martin Dreyling, MD, University Hospital LMU Munich, in Germany, discusses the final follow-up results of the TRIANGLE study ...

Venetoclax is under clinical development by AbbVie and currently in Phase II for Relapsed Acute Myeloid Leukemia.

Patients will be randomized 2:2:1 into three treatment arms. In Arms A and B, patients will receive Vanflyta or placebo, respectively, in combination with cytarabine and anthracycline induction and ...

Arms A and B will compare the therapy and a placebo, both in conjunction with cytarabine and anthracycline induction, and cytarabine consolidation chemotherapy. This will be followed by up to ...

INR:6711. kerala football team vs meghalaya football team standings The price of cytarabine has increased by 120%, and t ...